Innovative marketing programs for the pharmaceutical industry
The Kalvistas Pharmaceuticals stock was up 1.2% to $1,814 per share on Friday.
The stock has been on a tear since its July 1 IPO, gaining 5.3% so far this year.
It’s been outperforming many other stocks.
In fact, Kalvistas shares were the highest of any pharmaceutical company in August.
The stock is up 9.7% in the last three months of the year.
By JEFFREY STEWART | 07/04/17 08:00:00 AM EDT | Updated 07/05/17 07:03:36 AM EDT The U.S. Supreme Court ruled that ...
A year ago, when the Trump administration announced the first version of the Trump Drug Enforcement Administration’s new drug list, ...
I’m sure that many of you are familiar with the amag patent, which is a patent for a generic form ...